U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application
If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins Sunvozertinib's NDA was submitted based on the multinational pivotal WU-KONG1 Part B...
Audit finds no irregularities in Nagad
DHAKA, Bangladesh, Dec. 5, 2024 /PRNewswire/ -- An independent audit has not found any evidence of wrongdoings in Nagad, a leading mobile financial service provider based in Bangladesh, thus validating this MFS company's compliance with all...